2025
Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.
Saba N, Flamand Y, Lin D, Chung C, McDonald M, Flampouri S, Khan S, Snyderman C, Hanna E, El-Sayed I, Solares C, Le C, Ghaly M, Hwang P, Shin D, Axelrod R, Ikpeazu C, Adkins D, Duan F, Cohen M, Samuels M, Swiecicki P, Subramaniam R, Chakravarthy A, Burtness B. Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. Clinical Cancer Research 2025, 31: 2339-2346. PMID: 40227186, PMCID: PMC12165817, DOI: 10.1158/1078-0432.ccr-24-4085.Peer-Reviewed Original ResearchConceptsSinus squamous cell carcinomaNeoadjuvant chemotherapySquamous cell carcinomaOverall survivalArm BOne-sided alphaArm ACell carcinomaRandomized studyArm A versus BSP ratesGrade 5 eventsCo-primary objectivesSingle-institution studyA versus BLog-rank testFisher's exact testPreservation rateExact testChemotherapyOrgan preservationSurgeryPatientsT3/T4aCarcinoma
2024
850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
Saba N, Flamand Y, Lin D, Chung C, McDonald M, Flampouri S, Khan S, Snyderman C, Hanna E, El-Sayed Y, Solares C, Duan F, Ho A, Samuels M, Swiecicki P, Subramaniam R, Chakravarthy A, Burtness B. 850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163). Annals Of Oncology 2024, 35: s614. DOI: 10.1016/j.annonc.2024.08.911.Peer-Reviewed Original Research
2022
Larynx Cancer
Fan D, Kang J, Yu Y, Cahlon O, Riaz N, Lee N. Larynx Cancer. Practical Guides In Radiation Oncology 2022, 45-60. DOI: 10.1007/978-3-030-99590-4_4.Peer-Reviewed Original ResearchPostoperative radiotherapyLarynx cancerEarly stage squamous cell carcinomaOrgan preservation therapyEarly-stage diseaseLymph node metastasisAdvanced larynx cancerSquamous cell carcinomaStandard of careHigh-risk casesPre-treatment evaluationCommon clinical scenariosThin-cut CTPET/CTDefinitive chemoradiotherapyAdvanced diseaseLocoregional recurrencePreservation therapyGlottic larynxNode metastasisSubglottic extensionCell carcinomaLaryngeal cancerPhysical examOrgan preservationOutcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer
Eita A, Mohamed N, Rybkin A, Kang J, Fiasconaro M, Zhigang Z, Zakeri K, Yu Y, Sadaka E, Sherman E, Dunn L, Cracchiolo J, Wong R, Cohen M, Lee N. Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. The Laryngoscope 2022, 133: 1138-1145. PMID: 35801573, PMCID: PMC10547133, DOI: 10.1002/lary.30279.Peer-Reviewed Original ResearchConceptsUnivariate analysisLocoregional failureT4 laryngealNonoperative managementHypopharyngeal cancerRadiation therapyPercutaneous endoscopic gastrostomy tubeHypopharynx cancer patientsYear OS ratesDisease-free survivalNon-surgical managementHypopharynx groupsInoperable diseaseLast followUnresectable diseaseChemoradiation therapyNodal statusGastrostomy tubeHypopharynx cancerOS ratesStage T4Cancer patientsFunctional outcomeTracheostomy tubeOrgan preservationRevisiting the Principles of Preservation in an Era of Pandemic Obesity
Langford JT, DiRito JR, Doilicho N, Chickering GR, Stern DA, Ouyang X, Mehal W, Tietjen GT. Revisiting the Principles of Preservation in an Era of Pandemic Obesity. Frontiers In Immunology 2022, 13: 830992. PMID: 35432296, PMCID: PMC9011385, DOI: 10.3389/fimmu.2022.830992.Peer-Reviewed Original ResearchConceptsDeceased donorsOrgan preservationDonor populationIschemia-reperfusion injuryCurrent obesity epidemicHealthy donor populationPandemic obesityObese donorsReperfusion injuryMetabolic dysfunctionObesity epidemicObesitySignificant declineOrgansDonorsPopulationCurrent practiceDysfunctionTransplantInjury
2018
Emerging Innovations in Liver Preservation and Resuscitation
Kim J, Zimmerman M, Hong J. Emerging Innovations in Liver Preservation and Resuscitation. Transplantation Proceedings 2018, 50: 2308-2316. PMID: 30316348, DOI: 10.1016/j.transproceed.2018.03.080.Peer-Reviewed Original ResearchConceptsOrthotopic liver transplantationPrimary nonfunctionIncreased susceptibility to ischemia-reperfusion injuryMachine perfusionClinical trialsOutcome of orthotopic liver transplantationEra of organ shortageSusceptible to ischemia-reperfusion injuryMarginal graftsIncidence of primary nonfunctionNormothermic MPIschemia-reperfusion injuryMethods of organ preservationMarginal liver graftsDecreasing oxygen demandBiliary complicationsOrgan preservation timeLiver transplantationLiver graftsIncreased riskOrgan preservationHypothermic MPAnimal studiesBlood flow rateOrgan shortage
2017
Tissue conservation for transplantation
Krezdorn N, Tasigiorgos S, Wo L, Turk M, Lopdrup R, Kiwanuka H, Win T, Bueno E, Pomahac B. Tissue conservation for transplantation. Innovative Surgical Sciences 2017, 2: 171-187. PMID: 31579751, PMCID: PMC6754021, DOI: 10.1515/iss-2017-0010.Peer-Reviewed Original ResearchOrgan preservationLong-term allograft functionPreservation of organsStatic cold storageAllograft functionSubsequent reperfusionIschemic preconditioningPathophysiological changesMechanical perfusionTransplantationTissue conservationCurrent literature pointsTherapeutic additivesGold standardPreservation protocolsOrgansCurrent bodyTissueReperfusionIschemiaInjuryPerfusion
2014
Fortschritte in der Gesichtstransplantation
Kueckelhaus M, Lehnhardt M, Fischer S, Eriksson E, Pomahac B, Hirsch T. Fortschritte in der Gesichtstransplantation. Handchirurgie · Mikrochirurgie · Plastische Chirurgie 2014, 46: 206-213. PMID: 25162238, DOI: 10.1055/s-0034-1385850.Peer-Reviewed Original ResearchConceptsVascularised composite allotransplantationFace transplantationLife-threatening side effectsSolid organ transplantationDifferent transplant centersImmunosuppressive regimensMaintenance immunosuppressionVCA proceduresImmunosuppressive strategiesTransplant centersPatients' qualityLifelong immunosuppressionOrgan preservationSurgical techniqueOrgan transplantationComposite allograftsComposite allotransplantationSide effectsTransplantationFunctional reintegrationImmunosuppressionAnatomic structuresImmunogenic partFirst caseDifferent protocols
2010
Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).
Wanebo H, Ghebremichael M, Burtness B, Ridge J, Spencer S, Rosen F, Hancock M, Tolba K, Forastiere A. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal Of Clinical Oncology 2010, 28: 5513-5513. DOI: 10.1200/jco.2010.28.15_suppl.5513.Peer-Reviewed Original Research
2004
Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up
Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Haffty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL. Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up. Journal Of Clinical Oncology 2004, 22: 3061-3069. PMID: 15284256, DOI: 10.1200/jco.2004.01.108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarcinoma, Squamous CellCisplatinCombined Modality TherapyDrug Administration ScheduleFemaleFluorouracilFollow-Up StudiesHead and Neck NeoplasmsHumansLeucovorinMaleMiddle AgedQuality of LifeRemission InductionSurvival RateTreatment OutcomeConceptsConcurrent cisplatin chemoradiotherapyComplete response rateInduction chemotherapyCisplatin chemoradiotherapyOrgan preservationResponse rateAdvanced headGrade 3Survival rateProgression-free survival ratesNeck squamous cell carcinomaCommon grade 3Courses of cisplatinPartial response ratePhase II studyOverall survival ratePoor functional outcomeSquamous cell carcinomaExternal beam radiotherapyExcellent PFSResectable HNSCCAdvanced diseaseConcurrent chemoradiotherapyPersistent dysphagiaII study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply